LBF20207PG29: Difference between revisions
No edit summary |
No edit summary |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=XPR1713 | |LipidBank=XPR1713 | ||
|LipidMaps=LMFA03010024 | |LipidMaps=LMFA03010024 | ||
|SysName=9- | |SysName=9-Oxo- (11alpha,15S,19R) -trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&19 (R) -hydroxy Prostaglandin E_2&&9- | |Common Name=&&19(R) -hydroxy Prostaglandin E_2&&9-Oxo- (11alpha,15S,19R) -trihydroxy-prosta- (5Z,13E) -dien-1-oic acid | ||
|Source= | |Source= | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=19(R)-hydroxy PGE2 is a potent smooth muscle relaxant and a selective agonist for the EP2 receptor.[[Reference:Kelly_RW:Taylor_PL:Hearn_JP:Short_RV:Martin_DE:Marston_JH:,Nature,1976,260,544|{{RelationTable/GetFirstAuthor|Reference:Kelly_RW:Taylor_PL:Hearn_JP:Short_RV:Martin_DE:Marston_JH:,Nature,1976,260,544}}]][[Reference:Woodward_DF:Protzman_CE:Krauss_AH:Williams_LS:,Prostaglandins,1993,46,371|{{RelationTable/GetFirstAuthor|Reference:Woodward_DF:Protzman_CE:Krauss_AH:Williams_LS:,Prostaglandins,1993,46,371}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 08:31, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1713 |
| LipidMaps | LMFA03010024 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG29 |
| 19(R) -hydroxy Prostaglandin E2 | |
|---|---|
| |
| Structural Information | |
| 9-Oxo- (11α,15S,19R) -trihydroxy-prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C20H32O6 |
| Exact Mass | 368.219888756 |
| Average Mass | 368.46448 |
| SMILES | [C@H]([C@@H](C=C[C@H](O)CCC[C@@H](C)O)1)(C(C[C@H]1O)=O)CC=CCCCC(O)=O |
| Physicochemical Information | |
| 19(R)-hydroxy PGE2 is a potent smooth muscle relaxant and a selective agonist for the EP2 receptor. Kelly_RW et al. Woodward_DF et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
